Immunotherapeutic technology developer Aethlon Medical, Inc. has undergone a research and completed “in vitro” studies to identify Zika virus in Australia and abroad.
The California-based infectious disease and cancer immune developer made the announcement on Thursday, claiming their discovery of the way in which Zika can be identified and diagnosed rapidly using the Aethlon Hemopurifier®. It will be the most appropriate broad-spectrum treatment discovered to act as a countermeasure against viral pathogens that are either untreatable or are resistant to anti-viral drug therapies.
At the moment, the invention is being examined through an FDA-approved feasibility study. The San Diego company initially conducted studies on Zika virus using small-scale versions of the Hemopurifier. It resulted in 95 percent clearance rate of the virus from a body’s fluid in almost five to six hours.
“As a result of our research team’s validation of Zika capture, we have further reinforced the potential of our Hemopurifier to be a first line of defense against the growing list of infectious viral pathogens that are not addressed with traditional drug or vaccine therapies,” Aethlon Chairman and CEO Jim Joyce said in a press release.
Though there are rare cases of deaths and hospitalizations relating to Zika infection, its worse effects on a newborn make it important to make the disease identifiable at an early stage. The transfusion of the infection from mother to child leads to microcephaly that restricts the brain development both in size and capabilities. However, recently, scientists have found that the effect is not limited to improper development of the head in terms of size and brain cognitive factor but also leads to arthrogryposis. It is the condition that leads to deformities of joints in a newbie.
Mass Device reported that Aethlon announced an extension of its contract with Devense Advanced Research Projects Agency (DARPA). The contract was signed to develop a device that can help in reduction of sepsis incidents. It is a fatal infection found in combat-injured soldiers. The immune developer and DARPA have been working in association since September 2011.